Susquehanna Fundamental Investments LLC Acquires Shares of 1,301,772 Pfizer Inc. (NYSE:PFE)

Susquehanna Fundamental Investments LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,301,772 shares of the biopharmaceutical company's stock, valued at approximately $34,536,000. Pfizer comprises 0.5% of Susquehanna Fundamental Investments LLC's portfolio, making the stock its 26th largest position.

A number of other hedge funds have also bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter valued at $33,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $29.64.

Pfizer Price Performance

Shares of PFE stock traded up $0.42 during trading on Wednesday, hitting $24.21. The company had a trading volume of 26,018,296 shares, compared to its average volume of 40,765,382. The stock's 50-day moving average is $24.48 and its two-hundred day moving average is $25.86. The stock has a market capitalization of $137.31 billion, a price-to-earnings ratio of 17.17, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.10%. Pfizer's dividend payout ratio (DPR) is 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.